Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | RAB9A | P51151 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 1/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5324400 | 0.89 | SMN1; SMN2 (0.42) | SMN1; SMN2RAB9AMAPTTP53MAPK1 | |
| SCHEMBL5327618 | 0.88 | GLA (0.38) | RAB9AMAPTNPC1ALDH1A1GAA | |
| Bicarbonate SCHEMBL5984921 | 0.87 | GLA (0.37) | RAB9ANPC1ALDH1A1GAAKMT2A | |
| SCHEMBL4994479 | 0.84 | KMT2A (0.36) | RAB9ANPC1ALDH1A1GAAKMT2A | |
| SCHEMBL5329533 | 0.84 | CYP3A4 (0.36) | SMN1; SMN2RAB9AMAPTTP53NPC1 | |
| Bicarbonate SCHEMBL4976269 | 0.84 | KMT2A (0.35) | RAB9ANPC1ALDH1A1GAAKMT2A | |
| SCHEMBL5558310 | 0.82 | MAPT (0.39) | SMN1; SMN2RAB9AMAPTTP53MAPK1 | |
| SCHEMBL5559185 | 0.82 | KMT2A (0.42) | SMN1; SMN2RAB9AMAPTTP53ALDH1A1 | |
| Formic Acid SCHEMBL4976263 | 0.81 | HSD11B1 (0.34) | SMN1; SMN2RAB9AMAPTTP53MAPK1 | |
| SCHEMBL5328503 | 0.81 | ADRA1D (0.40) | RAB9ATP53NPC1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007141253-A1 | PROCESS FOR THE PRODUCTION OF INTERMEDIATES FOR THE PREPARATION OF TRICYCLIC IMIDAZOPYRIDINES | NYCOMED GMBH (DE) | 2007-12-13 | — | — | WO | disclosed |
| US-7223771-B2 | Tricyclic imidazopyridines | ALTANA PHARMA AG (DE) | 2007-05-29 | — | — | US | disclosed |
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | ALTANA PHARMA AG (DE) | 2007-03-22 | — | — | US | disclosed |
| EP-1696921-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | Altana Pharma AG (DE) | 2006-09-06 | — | — | EP | disclosed |
| EP-1419163-B9 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2005-11-09 | — | — | EP | disclosed |
| WO-2005058325-A1 | TRICYCLIC IMIDAZOPYRIDINES FOR USE AS GASTRIC SECRETION INHIBITORS | ALTANA PHARMA AG (DE) | 2005-06-30 | — | — | WO | disclosed |
| EP-1419163-B1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2005-06-15 | — | — | EP | disclosed |
| US-20050049272-A1 | Gastrointestinal disorders; inhibiting gastric acid secretion; such as 2,3-dimethyl-9-(2-ethyl-6-methyl-phenyl)-7H-8,9-dihydro-pyrano[2,3-c]-imidazo[1,2-a]pyridine-6-(N,N-diethyl)carbamide | ALTANA PHARMA AG (DE) | 2005-03-03 | — | — | US | disclosed |
| EP-1419163-A1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA Pharma AG (DE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014123-A1 | TRICYCLIC IMIDAZOPYRIDINES | ALTANA PHARMA AG (DE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049272-A1 | Gastrointestinal disorders; inhibiting gastric acid secretion; such as 2,3-dimethyl-9-(2-ethyl-6-methyl-phenyl)-7H-8,9-dihydro-pyrano[2,3-c]-imidazo[1,2-a]pyridine-6-(N,N-diethyl)carbamide | GIPR, GRPR, PGC | SMN1; SMN2 4215/4885RAB9A 66/4885MAPT 4539/4885 |
| US-20070066674-A1 | Tricyclic imidzopyridines for use as gastric secretion inhibitors | GIPR, SLC10A2, GRPR | SMN1; SMN2 4793/4885RAB9A 1627/4885MAPT 4431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.